Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions
Phase 1
Completed
- Conditions
- Endocrine, Nutritional and Metabolic Diseases
- Interventions
- Drug: CKD-387Drug: D484
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT06399068
- Locations
- 🇰🇷
Bumin Hospital, Seoul, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions
Phase 1
Completed
- Conditions
- Endocrine, Nutritional and Metabolic Diseases
- Interventions
- Drug: CKD-387Drug: D484
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 37
- Registration Number
- NCT06399055
- Locations
- 🇰🇷
Bumin Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect of CKD-378
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-378, QD, PO
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 31
- Registration Number
- NCT06386328
- Locations
- 🇰🇷
Gimpo Woori hospital, Gimpo-si, Gyeonggi-do, Korea, Republic of
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic After Oral Administration of CKD-341 and D956 in Healthy Adults
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-341, D956
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 51
- Registration Number
- NCT06281132
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of
A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: CKD-379(Empagliflozin+sitagliptin+metformin) Test drugDrug: CKD-379(Empagliflozin+sitagliptin+metformin) Reference drug
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT06204107
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- Drug: D064 and D702, QDDrug: D064 and Placebo of D702, QDDrug: Placebo of D064 and D702, QD
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 235
- Registration Number
- NCT06121518
- Locations
- 🇰🇷
Hanyang University Seoul Hospital, Seoul, Seongdong-gu, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)
Phase 1
Completed
- Conditions
- HypertensionDyslipidemias
- Interventions
- Drug: CKD-348(6)Drug: CKD-828, D097, D337
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 63
- Registration Number
- NCT06112678
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
Phase 1
Recruiting
- Conditions
- Benign Prostate Hypertrophy(BPH)
- Interventions
- Drug: CKD-846Drug: D091
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT06110923
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)
Phase 1
Completed
- Conditions
- Dyslipidemias
- Interventions
- Drug: CKD-391(2)Drug: CKD-331, D337
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 66
- Registration Number
- NCT06088017
- Locations
- 🇰🇷
Bumin hopspital, Seoul, Seoul, Gangseo-gu, Korea, Republic of
MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients
Phase 4
Recruiting
- Conditions
- Kidney Transplant
- Interventions
- Drug: Mycophenolate mofetil Tablet/CapsuleDrug: Myreptic-N Tablet
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 158
- Registration Number
- NCT06044493
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath